Loading EW detail
Loading ticker data...
Loading EW detail
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally.
It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors.
Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Chart data unavailable
Edwards Lifesciences Corporation (NYSE: EW - Get Free Report) VP Donald Bobo, Jr. sold 22,680 shares of the stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $80.16, for a total value of $1,818,028.80. Following the completion of the transaction, the vice president owned 21,266 shares in the
Cardiovascular disease may be one of medicine’s oldest battlegrounds, but some of its most important technologies are still evolving — and not always as...
Tilray Inc (NASDAQ:TLRY) earned a repeat ‘Buy’ rating from Jefferies analysts after what it described as a solid third quarter earnings report, pointing to...
Foundayo launches on April 6 at the same price as Novo's pill, threatening to reshape the $50 billion obesity drug market before Novo's first-quarter...
The forex market now turns over $9.6 trillion every single day. That figure, confirmed by the Bank for International Settlements in its 2025 Triennial...
Boston Common Asset Management LLC boosted its holdings in Edwards Lifesciences Corporation (NYSE: EW) by 6.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 144,703 shares of the medical research company's stock after buying an additional 9,028 shares during the quarter.
NEW ORLEANS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data on the EVOQUE transcatheter tricuspid valve replacement (TTVR) system at the American College of Cardiology Annual Scientific Session (ACC.26), demonstrating significant and sustained patient benefits including lower mortality when accounting for patient crossover, extending the findings presented at the European Society of Cardiology Congress (ESC 2025). The new TRISCEND II trial data presented today during.
Edwards Lifesciences (NYSE: EW - Get Free Report) and ERBA Diagnostics (OTCMKTS:ERBA - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, earnings, dividends, profitability and analyst recommendations. Institutional and Insider Ownership 79.5% of Edwards Lifesciences
Brevan Howard Capital Management LP lowered its stake in shares of Edwards Lifesciences Corporation (NYSE: EW) by 41.7% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,272 shares of the medical research company's stock after selling 33,100 shares during
Edwards Lifesciences delivered 11% revenue growth in 2025, driven by robust TAVR and accelerating TMTT businesses. Edwards Lifesciences guides for 8-10% sales growth and adjusted EPS of $2.90-$3.05 in 2026, with TMTT sales expected to rise 40%. Valuation has compressed to 26x forward earnings, supported by a strong net cash position and ongoing share repurchases.
Banco Bilbao Vizcaya Argentaria S.A. lifted its position in Edwards Lifesciences Corporation (NYSE: EW) by 9.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 218,749 shares of the medical research company's stock after acquiring an additional 18,498 shares
Banque Transatlantique SA trimmed its position in Edwards Lifesciences Corporation (NYSE: EW) by 32.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,434 shares of the medical research company's stock after selling 18,134 shares during the
EW shares jump 22.1% in a year as growth in TMTT and strong adoption of PASCAL, EVOQUE and SAPIEN technologies fuel momentum.
Edwards Lifesciences Corporation (EW) Presents at Leerink Global Healthcare Conference 2026 Transcript
Edwards Lifesciences Corporation (EW) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
